N-[9-[(2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-oxo-1H-purin-2-yl]acetamide

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: N-[9-[(2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-oxo-1H-purin-2-yl]acetamide
• 化学式: C₁₂H₁₅N₅O₅
• 分子量: 309.28
• InChiKey: GPNYRCHLEYXTPO-MVKOHCKWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  138
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Method for the treatment or prevention of flavivirus infections using nucleoside analogues
  申请人：——

  公开号：US20020019363A1

  公开（公告）日：2002-02-14

  The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula I or a pharmaceutically acceptable salt thereof.

  本发明涉及一种使用核苷类似物在宿主体内治疗或预防黄病毒感染的方法，包括给予具有公式I或其药学上可接受的盐的治疗有效量的化合物。
• METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS USING NUCLEOSIDE ANALOGUES
  申请人：Shire BioChem Inc.

  公开号：EP1296690A2

  公开（公告）日：2003-04-02
• Method for the treatment or prevention of Flavivirus infections using nucleoside analogues
  申请人：——

  公开号：US20040248844A1

  公开（公告）日：2004-12-09

  The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula I or a pharmaceutically acceptable salt thereof.
• US6784161B2
  申请人：——

  公开号：US6784161B2

  公开（公告）日：2004-08-31
• [EN] METHOD FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS USING NUCLEOSIDE ANALOGUES<br/>[FR] METHODE DE TRAITEMENT OU DE PREVENTION D'INFECTIONS A FLAVIVIRUS A L'AIDE D'ANALOGUES NUCLEOSIDIQUES
  申请人：IAF BIOCHEM INT

  公开号：WO2001060315A2

  公开（公告）日：2001-08-23

  The present invention relates to a method for the treatment or prevention of Flavivirus including hepatitis C virus infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having formula (I) or a pharmaceuticall acceptable salt thereof.